Skip to content
DataLookout
Start free
Menu

NCT05463796

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 3 years later.

See at-risk trials from Dana-Farber Cancer Institute

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 8 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Mar 25, 2027 to Mar 25, 2030
    • Study completion moved earlier from Mar 25, 2032 to Mar 25, 2031
    • Publications: 1 to 2
    v11
  2. Primary completion date: Mar 25, 2026 to Mar 25, 2027v10
  3. Eligibility criteria shortened, about 6 wordsv8
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 31, 2023 to Apr 25, 2023
    • Site details revised
    v5
  5. Start date: Jan 2023 to Mar 31, 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Nov 2022 to Jan 2023v3
  2. Site contact updatedv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.
Timeframe: 5 years

Arms and interventions

HEREDITARY RISK

Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues

EXPOSED HIGH RISK

Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues

PRECURSOR LESIONS

Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues

FAMILY MEMBERS

These family members will be identified by the patients participating in the study. Blood, buccal cells, or saliva or oral rinses will be collected in one of three ways from family members of patients (i) at the time of consent; (ii) via a mailed blood kit or saliva kit; or (iii) at a separate appointment scheduled by the consented participant

Other: Samples

Sites

1 site in 1 country

  • Dana Farber Cancer InstituteBoston, Massachusetts, United States